Nimodipine extended-release tablets
Function and Efficacy
Nimodipine is a Ca2 channel blocker. Under normal circumstances, the contraction of smooth muscle depends on the entry of Ca2 into the cell, causing the depolarization of the transmembrane current. Nimodipine achieves the purpose of relieving vasospasm by effectively preventing Ca2 from entering the cell and inhibiting the contraction of smooth muscle. Animal experiments have shown that the effect of nimodipine on cerebral arteries is much stronger than that on arteries in other parts of the body, and because it has a high lipophilic characteristic, it is easy to pass through the blood-brain barrier. When used for the treatment of subarachnoid hemorrhage, the concentration in cerebrospinal fluid can reach 12.5ng/ml. It can be inferred that it can be used clinically to prevent vasospasm after subarachnoid hemorrhage, but the mechanism of action of this drug in human application is still unclear. In addition, it also has the effect of protecting and promoting memory and promoting intellectual recovery. Therefore, it can selectively act on cerebral vascular smooth muscle, dilate cerebral blood vessels, increase cerebral blood flow, and significantly reduce ischemic brain damage caused by vasospasm.
Ingredients
Nimodipine.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| NimodipineIngredients |
Nimodipine is a Ca2 channel blocker that inhibits smooth muscle contraction and relieves vasospasm by preventing Ca2 from entering cells. It has a strong effect on cerebral arteries and can pass through the blood-brain barrier to prevent vasospasm after subarachnoid hemorrhage, protect and promote memory, promote intellectual recovery, dilate cerebral blood vessels, increase cerebral blood flow, and reduce ischemic brain damage. More |
66085-59-4 | 17 |
Appearance
This product is a light yellow tablet, odorless, tasteless, and not stable to light.
Indication
Used for ischemic cerebrovascular disease, migraine, cerebral vasospasm caused by mild subarachnoid hemorrhage, sudden deafness and mild to moderate hypertension.
Usage and Dosage
Oral administration: 30-60 mg at a time, twice a day.
Adverse Reactions
The following adverse reactions may occur with the regular-release preparation of nimodipine: feeling of heat, flushing of the skin, drop in blood pressure (especially in patients with pre-existing high blood pressure), increased heart rate, dizziness, headache, gastrointestinal discomfort, weakness, and peripheral edema. A small number of patients may experience symptoms of overreaction of the central nervous system, such as insomnia, restlessness, agitation, irritability, and sweating. Some patients may experience excessive exercise, depression, and thrombocytopenia.
Precautions
Patients with severe liver damage are contraindicated. It is not recommended to take nimodipine and anti-epileptic drugs at the same time.
Special Population Medication
Precautions for children: There is no research data on the use of this drug in patients under 18 years of age. Precautions for pregnancy and lactation: Pregnant and lactating women should follow the doctor's advice. Precautions for the elderly: Elderly patients with severe liver damage are prohibited from using this drug. Elderly patients should avoid using this drug with other calcium antagonists as much as possible.
Drug Interactions
1. When used in combination with other calcium ion antagonists that act on the cardiovascular system, it can increase the effectiveness of other calcium ion antagonists. 2. When nimodipine 90 mg/day is used in combination with cimetidine 1000 mg/day for more than one week, the blood concentration of nimodipine can increase by 50%, which may be related to the inhibition of nimodipine metabolism by cimetidine in the liver cytochrome P450.
Storage
Keep away from light, tightly closed and in a dry place.
Packaging Specification
60mg
Validity Period
24 months
Manufacturer
Jiangsu Kanion Pharmaceutical Co., Ltd.
-
Founded in:
1996-05-08 -
Address:
Lianyungang Economic and Technological Development Zone Jiangning Industrial City -
Tax NO.:
91320700138997640W -
Registered Funds:
581.797452 million yuan -
Website:
-
Email: